1793P RESILIENT part 1: Pharmacokinetics of second-line (2L) liposomal irinotecan in patients with small cell lung cancer (SCLC)

Authors :: Patricia Rich
V. Gutierrez Calderon
Atilio Navarro
R. Bernabe Caro
Theresa M. Hayes
O. Juan-Vidal
Bin Zhang
Paul A. Bunn
M. Jove Casulleras
Afshin Dowlati
Anna Pedret-Dunn
K. Brendel
Y. Moore
J. Kokhreidze
David R. Spigel
Luis Paz-Ares
Santiago Ponce
Y. Chen
Source :: Annals of Oncology. 31:S1038-S1039
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
medicine.medical_specialty
Second line
Pharmacokinetics
business.industry
Internal medicine
Medicine
Liposomal Irinotecan
In patient
Hematology
Non small cell
business

Full Text Access

Tools